People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

This new drug is a jab at Ozempic. Tirzepatide, a weekly injectable that rivals celebrity-favorite Wegovy, is one step closer to approval for weight loss by the Food and Drug Administration after ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.

For people who are obese and have type 2 diabetes, using Ozempic and other GLP-1 agonist drugs cuts the all-cause mortality rate by 30%, according to a new Use of GLP-1 agonists also cut the risk that ...

There’s a perception that Ozempic, Wegovy and Zepbound are all you need to live a healthier life. But diet and exercise still ...

Researchers followed 60,000 adults aged 40 and older—who took various types of antidiabetic medication—for seven years ...

,A weight-loss drug more effective than Ozempic and Wegovy has recently been approved in Australia. The drug, tirzepatide, is sold under the brand name Mounjaro and affects feelings of hunger and ...

Ozempic has become a blockbuster drug thanks to its ability to help people lose weight, but Mounjaro, another Type 2 diabetes treatment, appears to be far more effective for weight loss, a new ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

Tirzepatide — marketed by Lilly as Mounjaro and Zepbound — mimics the appetite-suppressing hormones GLP-1 and GIP. It’s been shown to spur greater, sustained weight loss than semaglutide.

Thrive Health Solutions also faces a lawsuit from drugmaker Eli Lilly, for allegedly making false claims about FDA approval ...